Guideline Title | Conditional | DocumentID | Decision Variable | DVCode | Action | ActionCode |
---|---|---|---|---|---|---|
Heart Failure 2017 ACC/AHA/HFSA | In patients presenting with dyspnea, measurement of natriuretic peptide biomarkers is useful to support a diagnosis or exclusion of Heart Failure. | 32480 | patients presenting with dyspnea | C2368562 | perform measurement of natriuretic peptide biomarkers | C2349989 |
Heart Failure 2017 ACC/AHA/HFSA | Radionuclide ventriculography or magnetic resonance imaging can be useful to assess LVEF and volume when echocardiography is inadequate. | 32490 | echocardiography is inadequate | C0013516 | magnetic resonance imaging | C4051978 |
Heart Failure 2017 ACC/AHA/HFSA | Radionuclide ventriculography or magnetic resonance imaging can be useful to assess LVEF and volume when echocardiography is inadequate. | 32490 | echocardiography is inadequate | C0013516 | magnetic resonance imaging | C0203201 |
Heart Failure 2017 ACC/AHA/HFSA | Radionuclide ventriculography or magnetic resonance imaging can be useful to assess LVEF and volume when echocardiography is inadequate. | 32490 | echocardiography is inadequate | C0013516 | magnetic resonance imaging | C0202674 |
Heart Failure 2017 ACC/AHA/HFSA | Radionuclide ventriculography or magnetic resonance imaging can be useful to assess LVEF and volume when echocardiography is inadequate. | 32490 | echocardiography is inadequate | C0013516 | magnetic resonance imaging | C4052128 |
Heart Failure 2017 ACC/AHA/HFSA | Radionuclide ventriculography or magnetic resonance imaging can be useful to assess LVEF and volume when echocardiography is inadequate. | 32490 | echocardiography is inadequate | C0013516 | magnetic resonance imaging | C1736655 |
Heart Failure 2017 ACC/AHA/HFSA | Radionuclide ventriculography or magnetic resonance imaging can be useful to assess LVEF and volume when echocardiography is inadequate. | 32490 | echocardiography is inadequate | C0013516 | magnetic resonance imaging | C3702005 |
Heart Failure 2017 ACC/AHA/HFSA | Radionuclide ventriculography or magnetic resonance imaging can be useful to assess LVEF and volume when echocardiography is inadequate. | 32490 | echocardiography is inadequate | C0013516 | magnetic resonance imaging | C0024487 |
Heart Failure 2017 ACC/AHA/HFSA | Radionuclide ventriculography or magnetic resonance imaging can be useful to assess LVEF and volume when echocardiography is inadequate. | 32490 | echocardiography is inadequate | C0013516 | magnetic resonance imaging | C0024485 |
Heart Failure 2017 ACC/AHA/HFSA | Radionuclide ventriculography or magnetic resonance imaging can be useful to assess LVEF and volume when echocardiography is inadequate. | 32490 | echocardiography is inadequate | C0013516 | magnetic resonance imaging | C1740479 |
Heart Failure 2017 ACC/AHA/HFSA | Radionuclide ventriculography or magnetic resonance imaging can be useful to assess LVEF and volume when echocardiography is inadequate. | 32490 | echocardiography is inadequate | C0013516 | magnetic resonance imaging | C1144703 |
Heart Failure 2017 ACC/AHA/HFSA | Radionuclide ventriculography or magnetic resonance imaging can be useful to assess LVEF and volume when echocardiography is inadequate. | 32490 | echocardiography is inadequate | C0013516 | magnetic resonance imaging | C1629029 |
Heart Failure 2017 ACC/AHA/HFSA | Radionuclide ventriculography or magnetic resonance imaging can be useful to assess LVEF and volume when echocardiography is inadequate. | 32490 | echocardiography is inadequate | C0013516 | magnetic resonance imaging | C3866181 |
Heart Failure 2017 ACC/AHA/HFSA | Radionuclide ventriculography or magnetic resonance imaging can be useful to assess LVEF and volume when echocardiography is inadequate. | 32490 | echocardiography is inadequate | C0013516 | magnetic resonance imaging | C3702016 |
Heart Failure 2017 ACC/AHA/HFSA | Radionuclide ventriculography or magnetic resonance imaging can be useful to assess LVEF and volume when echocardiography is inadequate. | 32490 | echocardiography is inadequate | C0013516 | magnetic resonance imaging | C3702236 |
Heart Failure 2017 ACC/AHA/HFSA | Radionuclide ventriculography or magnetic resonance imaging can be useful to assess LVEF and volume when echocardiography is inadequate. | 32490 | echocardiography is inadequate | C0013516 | magnetic resonance imaging | C0373168 |
Heart Failure 2017 ACC/AHA/HFSA | Radionuclide ventriculography or magnetic resonance imaging can be useful to assess LVEF and volume when echocardiography is inadequate. | 32490 | echocardiography is inadequate | C0013516 | magnetic resonance imaging | C0918145 |
Heart Failure 2017 ACC/AHA/HFSA | Radionuclide ventriculography or magnetic resonance imaging can be useful to assess LVEF and volume when echocardiography is inadequate. | 32490 | echocardiography is inadequate | C0013516 | magnetic resonance imaging | C0918142 |
Heart Failure 2017 ACC/AHA/HFSA | Radionuclide ventriculography or magnetic resonance imaging can be useful to assess LVEF and volume when echocardiography is inadequate. | 32490 | echocardiography is inadequate | C0013516 | magnetic resonance imaging | C4051979 |
Heart Failure 2017 ACC/AHA/HFSA | Radionuclide ventriculography or magnetic resonance imaging can be useful to assess LVEF and volume when echocardiography is inadequate. | 32490 | echocardiography is inadequate | C0013516 | magnetic resonance imaging | C2711860 |
Heart Failure 2017 ACC/AHA/HFSA | Radionuclide ventriculography or magnetic resonance imaging can be useful to assess LVEF and volume when echocardiography is inadequate. | 32490 | echocardiography is inadequate | C0013516 | magnetic resonance imaging | C0203792 |
Heart Failure 2017 ACC/AHA/HFSA | Radionuclide ventriculography or magnetic resonance imaging can be useful to assess LVEF and volume when echocardiography is inadequate. | 32490 | echocardiography is inadequate | C0013516 | magnetic resonance imaging | C0442972 |
Heart Failure 2017 ACC/AHA/HFSA | Radionuclide ventriculography or magnetic resonance imaging can be useful to assess LVEF and volume when echocardiography is inadequate. | 32490 | echocardiography is inadequate | C0013516 | magnetic resonance imaging | C0079595 |
Heart Failure 2017 ACC/AHA/HFSA | Radionuclide ventriculography or magnetic resonance imaging can be useful to assess LVEF and volume when echocardiography is inadequate. | 32490 | echocardiography is inadequate | C0013516 | magnetic resonance imaging | C3703842 |
Heart Failure 2017 ACC/AHA/HFSA | Radionuclide ventriculography or magnetic resonance imaging can be useful to assess LVEF and volume when echocardiography is inadequate. | 32490 | echocardiography is inadequate | C0013516 | magnetic resonance imaging | C3515978 |
Heart Failure 2017 ACC/AHA/HFSA | Radionuclide ventriculography or magnetic resonance imaging can be useful to assess LVEF and volume when echocardiography is inadequate. | 32490 | echocardiography is inadequate | C0013516 | magnetic resonance imaging | C0203835 |
Heart Failure 2017 ACC/AHA/HFSA | Radionuclide ventriculography or magnetic resonance imaging can be useful to assess LVEF and volume when echocardiography is inadequate. | 32490 | echocardiography is inadequate | C0013516 | magnetic resonance imaging | C3865779 |
Heart Failure 2017 ACC/AHA/HFSA | Heart FailurerEF NYHA class I?IV (Stage C) ACEI or ARB AND GDMT beta blocker; diuretics as needed (COR I) | 32516 | Stage C patient with HFrEF | C0973439 | treat with angiotensin-converting enzyme inhibitor or angiotensin receptor-blocker | C3865786 |
Heart Failure 2017 ACC/AHA/HFSA | Heart FailurerEF NYHA class I?IV (Stage C) ACEI or ARB AND GDMT beta blocker; diuretics as needed (COR I) | 32516 | Stage C patient with HFrEF | C3526570 | treat with angiotensin-converting enzyme inhibitor or angiotensin receptor-blocker | C3865786 |
Heart Failure 2017 ACC/AHA/HFSA | Heart FailurerEF NYHA class I?IV (Stage C) ACEI or ARB AND GDMT beta blocker; diuretics as needed (COR I) | 32516 | Stage C patient with HFrEF | C2065027 | treat with angiotensin-converting enzyme inhibitor or angiotensin receptor-blocker | C3865786 |
Heart Failure 2017 ACC/AHA/HFSA | Heart FailurerEF NYHA class I?IV (Stage C) ACEI or ARB AND GDMT beta blocker; diuretics as needed (COR I) | 32516 | Stage C patient with HFrEF | C3526576 | treat with angiotensin-converting enzyme inhibitor or angiotensin receptor-blocker | C3865786 |
Heart Failure 2017 ACC/AHA/HFSA | Heart FailurerEF NYHA class I?IV (Stage C) ACEI or ARB AND GDMT beta blocker; diuretics as needed (COR I) | 32516 | Stage C patient with HFrEF | C0973444 | treat with angiotensin-converting enzyme inhibitor or angiotensin receptor-blocker | C3865786 |
Heart Failure 2017 ACC/AHA/HFSA | Heart FailurerEF NYHA class I?IV (Stage C) ACEI or ARB AND GDMT beta blocker; diuretics as needed (COR I) | 32516 | Stage C patient with HFrEF | C3526564 | treat with angiotensin-converting enzyme inhibitor or angiotensin receptor-blocker | C3865786 |
Heart Failure 2017 ACC/AHA/HFSA | Heart FailurerEF NYHA class I?IV (Stage C) ACEI or ARB AND GDMT beta blocker; diuretics as needed (COR I) | 32516 | NYHA class I-IV | C0497659 | treat with angiotensin-converting enzyme inhibitor or angiotensin receptor-blocker | C3865786 |
Heart Failure 2017 ACC/AHA/HFSA | Heart FailurerEF NYHA class I?IV (Stage C) ACEI or ARB AND GDMT beta blocker; diuretics as needed (COR I) | 32516 | NYHA class I-IV | C0497660 | treat with angiotensin-converting enzyme inhibitor or angiotensin receptor-blocker | C3865786 |
Heart Failure 2017 ACC/AHA/HFSA | Heart FailurerEF NYHA class I?IV (Stage C) ACEI or ARB AND GDMT beta blocker; diuretics as needed (COR I) | 32516 | NYHA class I-IV | C0497661 | treat with angiotensin-converting enzyme inhibitor or angiotensin receptor-blocker | C3865786 |
Heart Failure 2017 ACC/AHA/HFSA | Heart FailurerEF NYHA class I?IV (Stage C) ACEI or ARB AND GDMT beta blocker; diuretics as needed (COR I) | 32516 | Stage C patient with HFrEF | C0973439 | treat with angiotensin-converting enzyme inhibitor or angiotensin receptor-blocker | C3865788 |
Heart Failure 2017 ACC/AHA/HFSA | Heart FailurerEF NYHA class I?IV (Stage C) ACEI or ARB AND GDMT beta blocker; diuretics as needed (COR I) | 32516 | Stage C patient with HFrEF | C3526570 | treat with angiotensin-converting enzyme inhibitor or angiotensin receptor-blocker | C3865788 |
Heart Failure 2017 ACC/AHA/HFSA | Heart FailurerEF NYHA class I?IV (Stage C) ACEI or ARB AND GDMT beta blocker; diuretics as needed (COR I) | 32516 | Stage C patient with HFrEF | C2065027 | treat with angiotensin-converting enzyme inhibitor or angiotensin receptor-blocker | C3865788 |
Heart Failure 2017 ACC/AHA/HFSA | Heart FailurerEF NYHA class I?IV (Stage C) ACEI or ARB AND GDMT beta blocker; diuretics as needed (COR I) | 32516 | Stage C patient with HFrEF | C3526576 | treat with angiotensin-converting enzyme inhibitor or angiotensin receptor-blocker | C3865788 |
Heart Failure 2017 ACC/AHA/HFSA | Heart FailurerEF NYHA class I?IV (Stage C) ACEI or ARB AND GDMT beta blocker; diuretics as needed (COR I) | 32516 | Stage C patient with HFrEF | C0973444 | treat with angiotensin-converting enzyme inhibitor or angiotensin receptor-blocker | C3865788 |
Heart Failure 2017 ACC/AHA/HFSA | Heart FailurerEF NYHA class I?IV (Stage C) ACEI or ARB AND GDMT beta blocker; diuretics as needed (COR I) | 32516 | Stage C patient with HFrEF | C3526564 | treat with angiotensin-converting enzyme inhibitor or angiotensin receptor-blocker | C3865788 |
Heart Failure 2017 ACC/AHA/HFSA | Heart FailurerEF NYHA class I?IV (Stage C) ACEI or ARB AND GDMT beta blocker; diuretics as needed (COR I) | 32516 | NYHA class I-IV | C0497659 | treat with angiotensin-converting enzyme inhibitor or angiotensin receptor-blocker | C3865788 |
Heart Failure 2017 ACC/AHA/HFSA | Heart FailurerEF NYHA class I?IV (Stage C) ACEI or ARB AND GDMT beta blocker; diuretics as needed (COR I) | 32516 | NYHA class I-IV | C0497660 | treat with angiotensin-converting enzyme inhibitor or angiotensin receptor-blocker | C3865788 |
Heart Failure 2017 ACC/AHA/HFSA | Heart FailurerEF NYHA class I?IV (Stage C) ACEI or ARB AND GDMT beta blocker; diuretics as needed (COR I) | 32516 | NYHA class I-IV | C0497661 | treat with angiotensin-converting enzyme inhibitor or angiotensin receptor-blocker | C3865788 |
Heart Failure 2017 ACC/AHA/HFSA | NYHA class II?IV, provided est. CrCl >30 mL/min & K+ <5.0 mEq/L implement Aldosterone antagonist (COR I) | 32517 | patient is NYHA class II–IV | C0497661 | implement aldosterone antagonist | C0373535 |
Heart Failure 2017 ACC/AHA/HFSA | NYHA class II?III, LVEF ?35%; (caveat: >1 y survival, >40 d post MI) implement implantable cardioverter-defibrillator | 32520 | NYHA class II–III | C0497659 | implement implantable cardioverter defibrillator | C3865424 |
Heart Failure 2017 ACC/AHA/HFSA | NYHA class II?III, LVEF ?35%; (caveat: >1 y survival, >40 d post MI) implement implantable cardioverter-defibrillator | 32520 | NYHA class II–III | C0497660 | implement implantable cardioverter defibrillator | C3865424 |
Heart Failure 2017 ACC/AHA/HFSA | NYHA class II?III, LVEF ?35%; (caveat: >1 y survival, >40 d post MI) implement implantable cardioverter-defibrillator | 32520 | NYHA class II–III | C0497661 | implement implantable cardioverter defibrillator | C3865424 |
Heart Failure 2017 ACC/AHA/HFSA | NYHA class II?III, LVEF ?35%; (caveat: >1 y survival, >40 d post MI) implement implantable cardioverter-defibrillator | 32520 | left ventricular ejection fraction ?35% | C3520484 | implement implantable cardioverter defibrillator | C3865424 |
Heart Failure 2017 ACC/AHA/HFSA | NYHA class II?III, LVEF ?35%; (caveat: >1 y survival, >40 d post MI) implement implantable cardioverter-defibrillator | 32520 | left ventricular ejection fraction ?35% | C1736907 | implement implantable cardioverter defibrillator | C3865424 |
Heart Failure 2017 ACC/AHA/HFSA | NYHA class II?III, LVEF ?35%; (caveat: >1 y survival, >40 d post MI) implement implantable cardioverter-defibrillator | 32520 | left ventricular ejection fraction ?35% | C1736638 | implement implantable cardioverter defibrillator | C3865424 |
Heart Failure 2017 ACC/AHA/HFSA | NYHA class II?III, LVEF ?35%; (caveat: >1 y survival, >40 d post MI) implement implantable cardioverter-defibrillator | 32520 | left ventricular ejection fraction ?35% | C3248278 | implement implantable cardioverter defibrillator | C3865424 |
Heart Failure 2017 ACC/AHA/HFSA | NYHA class II?III, LVEF ?35%; (caveat: >1 y survival, >40 d post MI) implement implantable cardioverter-defibrillator | 32520 | left ventricular ejection fraction ?35% | C3248277 | implement implantable cardioverter defibrillator | C3865424 |
Heart Failure 2017 ACC/AHA/HFSA | NYHA class II?III, LVEF ?35%; (caveat: >1 y survival, >40 d post MI) implement implantable cardioverter-defibrillator | 32520 | left ventricular ejection fraction ?35% | C3248276 | implement implantable cardioverter defibrillator | C3865424 |
Heart Failure 2017 ACC/AHA/HFSA | NYHA class II?III, LVEF ?35%; (caveat: >1 y survival, >40 d post MI) implement implantable cardioverter-defibrillator | 32520 | NYHA class II–III | C0497659 | implement implantable cardioverter defibrillator | C3869466 |
Heart Failure 2017 ACC/AHA/HFSA | NYHA class II?III, LVEF ?35%; (caveat: >1 y survival, >40 d post MI) implement implantable cardioverter-defibrillator | 32520 | NYHA class II–III | C0497660 | implement implantable cardioverter defibrillator | C3869466 |
Heart Failure 2017 ACC/AHA/HFSA | NYHA class II?III, LVEF ?35%; (caveat: >1 y survival, >40 d post MI) implement implantable cardioverter-defibrillator | 32520 | NYHA class II–III | C0497661 | implement implantable cardioverter defibrillator | C3869466 |
Heart Failure 2017 ACC/AHA/HFSA | NYHA class II?III, LVEF ?35%; (caveat: >1 y survival, >40 d post MI) implement implantable cardioverter-defibrillator | 32520 | left ventricular ejection fraction ?35% | C3520484 | implement implantable cardioverter defibrillator | C3869466 |
Heart Failure 2017 ACC/AHA/HFSA | NYHA class II?III, LVEF ?35%; (caveat: >1 y survival, >40 d post MI) implement implantable cardioverter-defibrillator | 32520 | left ventricular ejection fraction ?35% | C1736907 | implement implantable cardioverter defibrillator | C3869466 |
Heart Failure 2017 ACC/AHA/HFSA | NYHA class II?III, LVEF ?35%; (caveat: >1 y survival, >40 d post MI) implement implantable cardioverter-defibrillator | 32520 | left ventricular ejection fraction ?35% | C1736638 | implement implantable cardioverter defibrillator | C3869466 |
Heart Failure 2017 ACC/AHA/HFSA | NYHA class II?III, LVEF ?35%; (caveat: >1 y survival, >40 d post MI) implement implantable cardioverter-defibrillator | 32520 | left ventricular ejection fraction ?35% | C3248278 | implement implantable cardioverter defibrillator | C3869466 |
Heart Failure 2017 ACC/AHA/HFSA | NYHA class II?III, LVEF ?35%; (caveat: >1 y survival, >40 d post MI) implement implantable cardioverter-defibrillator | 32520 | left ventricular ejection fraction ?35% | C3248277 | implement implantable cardioverter defibrillator | C3869466 |
Heart Failure 2017 ACC/AHA/HFSA | NYHA class II?III, LVEF ?35%; (caveat: >1 y survival, >40 d post MI) implement implantable cardioverter-defibrillator | 32520 | left ventricular ejection fraction ?35% | C3248276 | implement implantable cardioverter defibrillator | C3869466 |
Heart Failure 2017 ACC/AHA/HFSA | NYHA class II?III, LVEF ?35%; (caveat: >1 y survival, >40 d post MI) implement implantable cardioverter-defibrillator | 32520 | NYHA class II–III | C0497659 | implement implantable cardioverter defibrillator | C3869464 |
Heart Failure 2017 ACC/AHA/HFSA | NYHA class II?III, LVEF ?35%; (caveat: >1 y survival, >40 d post MI) implement implantable cardioverter-defibrillator | 32520 | NYHA class II–III | C0497660 | implement implantable cardioverter defibrillator | C3869464 |
Heart Failure 2017 ACC/AHA/HFSA | NYHA class II?III, LVEF ?35%; (caveat: >1 y survival, >40 d post MI) implement implantable cardioverter-defibrillator | 32520 | NYHA class II–III | C0497661 | implement implantable cardioverter defibrillator | C3869464 |
Heart Failure 2017 ACC/AHA/HFSA | NYHA class II?III, LVEF ?35%; (caveat: >1 y survival, >40 d post MI) implement implantable cardioverter-defibrillator | 32520 | left ventricular ejection fraction ?35% | C3520484 | implement implantable cardioverter defibrillator | C3869464 |
Heart Failure 2017 ACC/AHA/HFSA | NYHA class II?III, LVEF ?35%; (caveat: >1 y survival, >40 d post MI) implement implantable cardioverter-defibrillator | 32520 | left ventricular ejection fraction ?35% | C1736907 | implement implantable cardioverter defibrillator | C3869464 |
Heart Failure 2017 ACC/AHA/HFSA | NYHA class II?III, LVEF ?35%; (caveat: >1 y survival, >40 d post MI) implement implantable cardioverter-defibrillator | 32520 | left ventricular ejection fraction ?35% | C1736638 | implement implantable cardioverter defibrillator | C3869464 |
Heart Failure 2017 ACC/AHA/HFSA | NYHA class II?III, LVEF ?35%; (caveat: >1 y survival, >40 d post MI) implement implantable cardioverter-defibrillator | 32520 | left ventricular ejection fraction ?35% | C3248278 | implement implantable cardioverter defibrillator | C3869464 |
Heart Failure 2017 ACC/AHA/HFSA | NYHA class II?III, LVEF ?35%; (caveat: >1 y survival, >40 d post MI) implement implantable cardioverter-defibrillator | 32520 | left ventricular ejection fraction ?35% | C3248277 | implement implantable cardioverter defibrillator | C3869464 |
Heart Failure 2017 ACC/AHA/HFSA | NYHA class II?III, LVEF ?35%; (caveat: >1 y survival, >40 d post MI) implement implantable cardioverter-defibrillator | 32520 | left ventricular ejection fraction ?35% | C3248276 | implement implantable cardioverter defibrillator | C3869464 |
Heart Failure 2017 ACC/AHA/HFSA | NYHA class II?III, LVEF ?35%; (caveat: >1 y survival, >40 d post MI) implement implantable cardioverter-defibrillator | 32520 | NYHA class II–III | C0497659 | implement implantable cardioverter defibrillator | C3869061 |
Heart Failure 2017 ACC/AHA/HFSA | NYHA class II?III, LVEF ?35%; (caveat: >1 y survival, >40 d post MI) implement implantable cardioverter-defibrillator | 32520 | NYHA class II–III | C0497660 | implement implantable cardioverter defibrillator | C3869061 |
Heart Failure 2017 ACC/AHA/HFSA | NYHA class II?III, LVEF ?35%; (caveat: >1 y survival, >40 d post MI) implement implantable cardioverter-defibrillator | 32520 | NYHA class II–III | C0497661 | implement implantable cardioverter defibrillator | C3869061 |
Heart Failure 2017 ACC/AHA/HFSA | NYHA class II?III, LVEF ?35%; (caveat: >1 y survival, >40 d post MI) implement implantable cardioverter-defibrillator | 32520 | left ventricular ejection fraction ?35% | C3520484 | implement implantable cardioverter defibrillator | C3869061 |
Heart Failure 2017 ACC/AHA/HFSA | NYHA class II?III, LVEF ?35%; (caveat: >1 y survival, >40 d post MI) implement implantable cardioverter-defibrillator | 32520 | left ventricular ejection fraction ?35% | C1736907 | implement implantable cardioverter defibrillator | C3869061 |
Heart Failure 2017 ACC/AHA/HFSA | NYHA class II?III, LVEF ?35%; (caveat: >1 y survival, >40 d post MI) implement implantable cardioverter-defibrillator | 32520 | left ventricular ejection fraction ?35% | C1736638 | implement implantable cardioverter defibrillator | C3869061 |
Heart Failure 2017 ACC/AHA/HFSA | NYHA class II?III, LVEF ?35%; (caveat: >1 y survival, >40 d post MI) implement implantable cardioverter-defibrillator | 32520 | left ventricular ejection fraction ?35% | C3248278 | implement implantable cardioverter defibrillator | C3869061 |
Heart Failure 2017 ACC/AHA/HFSA | NYHA class II?III, LVEF ?35%; (caveat: >1 y survival, >40 d post MI) implement implantable cardioverter-defibrillator | 32520 | left ventricular ejection fraction ?35% | C3248277 | implement implantable cardioverter defibrillator | C3869061 |
Heart Failure 2017 ACC/AHA/HFSA | NYHA class II?III, LVEF ?35%; (caveat: >1 y survival, >40 d post MI) implement implantable cardioverter-defibrillator | 32520 | left ventricular ejection fraction ?35% | C3248276 | implement implantable cardioverter defibrillator | C3869061 |
Heart Failure 2017 ACC/AHA/HFSA | NYHA class II?III, LVEF ?35%; (caveat: >1 y survival, >40 d post MI) implement implantable cardioverter-defibrillator | 32520 | NYHA class II–III | C0497659 | implement implantable cardioverter defibrillator | C3865425 |
Heart Failure 2017 ACC/AHA/HFSA | NYHA class II?III, LVEF ?35%; (caveat: >1 y survival, >40 d post MI) implement implantable cardioverter-defibrillator | 32520 | NYHA class II–III | C0497660 | implement implantable cardioverter defibrillator | C3865425 |
Heart Failure 2017 ACC/AHA/HFSA | NYHA class II?III, LVEF ?35%; (caveat: >1 y survival, >40 d post MI) implement implantable cardioverter-defibrillator | 32520 | NYHA class II–III | C0497661 | implement implantable cardioverter defibrillator | C3865425 |
Heart Failure 2017 ACC/AHA/HFSA | NYHA class II?III, LVEF ?35%; (caveat: >1 y survival, >40 d post MI) implement implantable cardioverter-defibrillator | 32520 | left ventricular ejection fraction ?35% | C3520484 | implement implantable cardioverter defibrillator | C3865425 |
Heart Failure 2017 ACC/AHA/HFSA | NYHA class II?III, LVEF ?35%; (caveat: >1 y survival, >40 d post MI) implement implantable cardioverter-defibrillator | 32520 | left ventricular ejection fraction ?35% | C1736907 | implement implantable cardioverter defibrillator | C3865425 |
Heart Failure 2017 ACC/AHA/HFSA | NYHA class II?III, LVEF ?35%; (caveat: >1 y survival, >40 d post MI) implement implantable cardioverter-defibrillator | 32520 | left ventricular ejection fraction ?35% | C1736638 | implement implantable cardioverter defibrillator | C3865425 |
Heart Failure 2017 ACC/AHA/HFSA | NYHA class II?III, LVEF ?35%; (caveat: >1 y survival, >40 d post MI) implement implantable cardioverter-defibrillator | 32520 | left ventricular ejection fraction ?35% | C3248278 | implement implantable cardioverter defibrillator | C3865425 |
Heart Failure 2017 ACC/AHA/HFSA | NYHA class II?III, LVEF ?35%; (caveat: >1 y survival, >40 d post MI) implement implantable cardioverter-defibrillator | 32520 | left ventricular ejection fraction ?35% | C3248277 | implement implantable cardioverter defibrillator | C3865425 |
Heart Failure 2017 ACC/AHA/HFSA | NYHA class II?III, LVEF ?35%; (caveat: >1 y survival, >40 d post MI) implement implantable cardioverter-defibrillator | 32520 | left ventricular ejection fraction ?35% | C3248276 | implement implantable cardioverter defibrillator | C3865425 |
Heart Failure 2017 ACC/AHA/HFSA | NYHA class II?III, LVEF ?35%; (caveat: >1 y survival, >40 d post MI) implement implantable cardioverter-defibrillator | 32520 | NYHA class II–III | C0497659 | implement implantable cardioverter defibrillator | C3865667 |
Heart Failure 2017 ACC/AHA/HFSA | NYHA class II?III, LVEF ?35%; (caveat: >1 y survival, >40 d post MI) implement implantable cardioverter-defibrillator | 32520 | NYHA class II–III | C0497660 | implement implantable cardioverter defibrillator | C3865667 |
Heart Failure 2017 ACC/AHA/HFSA | NYHA class II?III, LVEF ?35%; (caveat: >1 y survival, >40 d post MI) implement implantable cardioverter-defibrillator | 32520 | NYHA class II–III | C0497661 | implement implantable cardioverter defibrillator | C3865667 |
Heart Failure 2017 ACC/AHA/HFSA | NYHA class II?III, LVEF ?35%; (caveat: >1 y survival, >40 d post MI) implement implantable cardioverter-defibrillator | 32520 | left ventricular ejection fraction ?35% | C3520484 | implement implantable cardioverter defibrillator | C3865667 |
Heart Failure 2017 ACC/AHA/HFSA | NYHA class II?III, LVEF ?35%; (caveat: >1 y survival, >40 d post MI) implement implantable cardioverter-defibrillator | 32520 | left ventricular ejection fraction ?35% | C1736907 | implement implantable cardioverter defibrillator | C3865667 |
Heart Failure 2017 ACC/AHA/HFSA | NYHA class II?III, LVEF ?35%; (caveat: >1 y survival, >40 d post MI) implement implantable cardioverter-defibrillator | 32520 | left ventricular ejection fraction ?35% | C1736638 | implement implantable cardioverter defibrillator | C3865667 |
Heart Failure 2017 ACC/AHA/HFSA | NYHA class II?III, LVEF ?35%; (caveat: >1 y survival, >40 d post MI) implement implantable cardioverter-defibrillator | 32520 | left ventricular ejection fraction ?35% | C3248278 | implement implantable cardioverter defibrillator | C3865667 |
Heart Failure 2017 ACC/AHA/HFSA | NYHA class II?III, LVEF ?35%; (caveat: >1 y survival, >40 d post MI) implement implantable cardioverter-defibrillator | 32520 | left ventricular ejection fraction ?35% | C3248277 | implement implantable cardioverter defibrillator | C3865667 |
Heart Failure 2017 ACC/AHA/HFSA | NYHA class II?III, LVEF ?35%; (caveat: >1 y survival, >40 d post MI) implement implantable cardioverter-defibrillator | 32520 | left ventricular ejection fraction ?35% | C3248276 | implement implantable cardioverter defibrillator | C3865667 |
Heart Failure 2017 ACC/AHA/HFSA | NYHA class II?III, LVEF ?35%; (caveat: >1 y survival, >40 d post MI) implement implantable cardioverter-defibrillator | 32520 | NYHA class II–III | C0497659 | implement implantable cardioverter defibrillator | C3267145 |
Heart Failure 2017 ACC/AHA/HFSA | NYHA class II?III, LVEF ?35%; (caveat: >1 y survival, >40 d post MI) implement implantable cardioverter-defibrillator | 32520 | NYHA class II–III | C0497660 | implement implantable cardioverter defibrillator | C3267145 |
Heart Failure 2017 ACC/AHA/HFSA | NYHA class II?III, LVEF ?35%; (caveat: >1 y survival, >40 d post MI) implement implantable cardioverter-defibrillator | 32520 | NYHA class II–III | C0497661 | implement implantable cardioverter defibrillator | C3267145 |
Heart Failure 2017 ACC/AHA/HFSA | NYHA class II?III, LVEF ?35%; (caveat: >1 y survival, >40 d post MI) implement implantable cardioverter-defibrillator | 32520 | left ventricular ejection fraction ?35% | C3520484 | implement implantable cardioverter defibrillator | C3267145 |
Heart Failure 2017 ACC/AHA/HFSA | NYHA class II?III, LVEF ?35%; (caveat: >1 y survival, >40 d post MI) implement implantable cardioverter-defibrillator | 32520 | left ventricular ejection fraction ?35% | C1736907 | implement implantable cardioverter defibrillator | C3267145 |
Heart Failure 2017 ACC/AHA/HFSA | NYHA class II?III, LVEF ?35%; (caveat: >1 y survival, >40 d post MI) implement implantable cardioverter-defibrillator | 32520 | left ventricular ejection fraction ?35% | C1736638 | implement implantable cardioverter defibrillator | C3267145 |
Heart Failure 2017 ACC/AHA/HFSA | NYHA class II?III, LVEF ?35%; (caveat: >1 y survival, >40 d post MI) implement implantable cardioverter-defibrillator | 32520 | left ventricular ejection fraction ?35% | C3248278 | implement implantable cardioverter defibrillator | C3267145 |
Heart Failure 2017 ACC/AHA/HFSA | NYHA class II?III, LVEF ?35%; (caveat: >1 y survival, >40 d post MI) implement implantable cardioverter-defibrillator | 32520 | left ventricular ejection fraction ?35% | C3248277 | implement implantable cardioverter defibrillator | C3267145 |
Heart Failure 2017 ACC/AHA/HFSA | NYHA class II?III, LVEF ?35%; (caveat: >1 y survival, >40 d post MI) implement implantable cardioverter-defibrillator | 32520 | left ventricular ejection fraction ?35% | C3248276 | implement implantable cardioverter defibrillator | C3267145 |
Heart Failure 2017 ACC/AHA/HFSA | NYHA class II?III, LVEF ?35%; (caveat: >1 y survival, >40 d post MI) implement implantable cardioverter-defibrillator | 32520 | NYHA class II–III | C0497659 | implement implantable cardioverter defibrillator | C3695090 |
Heart Failure 2017 ACC/AHA/HFSA | NYHA class II?III, LVEF ?35%; (caveat: >1 y survival, >40 d post MI) implement implantable cardioverter-defibrillator | 32520 | NYHA class II–III | C0497660 | implement implantable cardioverter defibrillator | C3695090 |
Heart Failure 2017 ACC/AHA/HFSA | NYHA class II?III, LVEF ?35%; (caveat: >1 y survival, >40 d post MI) implement implantable cardioverter-defibrillator | 32520 | NYHA class II–III | C0497661 | implement implantable cardioverter defibrillator | C3695090 |
Heart Failure 2017 ACC/AHA/HFSA | NYHA class II?III, LVEF ?35%; (caveat: >1 y survival, >40 d post MI) implement implantable cardioverter-defibrillator | 32520 | left ventricular ejection fraction ?35% | C3520484 | implement implantable cardioverter defibrillator | C3695090 |
Heart Failure 2017 ACC/AHA/HFSA | NYHA class II?III, LVEF ?35%; (caveat: >1 y survival, >40 d post MI) implement implantable cardioverter-defibrillator | 32520 | left ventricular ejection fraction ?35% | C1736907 | implement implantable cardioverter defibrillator | C3695090 |
Heart Failure 2017 ACC/AHA/HFSA | NYHA class II?III, LVEF ?35%; (caveat: >1 y survival, >40 d post MI) implement implantable cardioverter-defibrillator | 32520 | left ventricular ejection fraction ?35% | C1736638 | implement implantable cardioverter defibrillator | C3695090 |
Heart Failure 2017 ACC/AHA/HFSA | NYHA class II?III, LVEF ?35%; (caveat: >1 y survival, >40 d post MI) implement implantable cardioverter-defibrillator | 32520 | left ventricular ejection fraction ?35% | C3248278 | implement implantable cardioverter defibrillator | C3695090 |
Heart Failure 2017 ACC/AHA/HFSA | NYHA class II?III, LVEF ?35%; (caveat: >1 y survival, >40 d post MI) implement implantable cardioverter-defibrillator | 32520 | left ventricular ejection fraction ?35% | C3248277 | implement implantable cardioverter defibrillator | C3695090 |
Heart Failure 2017 ACC/AHA/HFSA | NYHA class II?III, LVEF ?35%; (caveat: >1 y survival, >40 d post MI) implement implantable cardioverter-defibrillator | 32520 | left ventricular ejection fraction ?35% | C3248276 | implement implantable cardioverter defibrillator | C3695090 |
Heart Failure 2017 ACC/AHA/HFSA | NYHA class II?III, LVEF ?35%; (caveat: >1 y survival, >40 d post MI) implement implantable cardioverter-defibrillator | 32520 | NYHA class II–III | C0497659 | implement implantable cardioverter defibrillator | C1314164 |
Heart Failure 2017 ACC/AHA/HFSA | NYHA class II?III, LVEF ?35%; (caveat: >1 y survival, >40 d post MI) implement implantable cardioverter-defibrillator | 32520 | NYHA class II–III | C0497660 | implement implantable cardioverter defibrillator | C1314164 |
Heart Failure 2017 ACC/AHA/HFSA | NYHA class II?III, LVEF ?35%; (caveat: >1 y survival, >40 d post MI) implement implantable cardioverter-defibrillator | 32520 | NYHA class II–III | C0497661 | implement implantable cardioverter defibrillator | C1314164 |
Heart Failure 2017 ACC/AHA/HFSA | NYHA class II?III, LVEF ?35%; (caveat: >1 y survival, >40 d post MI) implement implantable cardioverter-defibrillator | 32520 | left ventricular ejection fraction ?35% | C3520484 | implement implantable cardioverter defibrillator | C1314164 |
Heart Failure 2017 ACC/AHA/HFSA | NYHA class II?III, LVEF ?35%; (caveat: >1 y survival, >40 d post MI) implement implantable cardioverter-defibrillator | 32520 | left ventricular ejection fraction ?35% | C1736907 | implement implantable cardioverter defibrillator | C1314164 |
Heart Failure 2017 ACC/AHA/HFSA | NYHA class II?III, LVEF ?35%; (caveat: >1 y survival, >40 d post MI) implement implantable cardioverter-defibrillator | 32520 | left ventricular ejection fraction ?35% | C1736638 | implement implantable cardioverter defibrillator | C1314164 |
Heart Failure 2017 ACC/AHA/HFSA | NYHA class II?III, LVEF ?35%; (caveat: >1 y survival, >40 d post MI) implement implantable cardioverter-defibrillator | 32520 | left ventricular ejection fraction ?35% | C3248278 | implement implantable cardioverter defibrillator | C1314164 |
Heart Failure 2017 ACC/AHA/HFSA | NYHA class II?III, LVEF ?35%; (caveat: >1 y survival, >40 d post MI) implement implantable cardioverter-defibrillator | 32520 | left ventricular ejection fraction ?35% | C3248277 | implement implantable cardioverter defibrillator | C1314164 |
Heart Failure 2017 ACC/AHA/HFSA | NYHA class II?III, LVEF ?35%; (caveat: >1 y survival, >40 d post MI) implement implantable cardioverter-defibrillator | 32520 | left ventricular ejection fraction ?35% | C3248276 | implement implantable cardioverter defibrillator | C1314164 |
Heart Failure 2017 ACC/AHA/HFSA | Aldosterone receptor antagonists (or mineralocorticoid receptor antagonists) are recommended in patients with NYHA class II–IV and who have LVEF of ?35%, unless contraindicated, to reduce morbidity and mortality. Patients with NYHA class II should have a history of prior cardiovascular hospitalization or elevated plasma natriuretic peptide levels to be considered for aldosterone receptor antagonists. Creatinine levels should be ?2.5 mg/dL in men or ?2.0 mg/dL in women (or estimated glomerular filtration rate >30 mL/min/1.73 m2) 2) and potassium levels should be <5.0 mEq/L. Careful monitoring of potassium levels, renal function, and diuretic dosing should be performed at initiation and closely followed thereafter to minimize risk of hyperkalemia and renal insufficiency. | 32563 | patients with NYHA class II–IV | C0497661 | Aldosterone receptor antagonists (or mineralocorticoid receptor antagonists) | C3708847 |
Heart Failure 2017 ACC/AHA/HFSA | Aldosterone receptor antagonists (or mineralocorticoid receptor antagonists) are recommended in patients with NYHA class II–IV and who have LVEF of ?35%, unless contraindicated, to reduce morbidity and mortality. Patients with NYHA class II should have a history of prior cardiovascular hospitalization or elevated plasma natriuretic peptide levels to be considered for aldosterone receptor antagonists. Creatinine levels should be ?2.5 mg/dL in men or ?2.0 mg/dL in women (or estimated glomerular filtration rate >30 mL/min/1.73 m2) 2) and potassium levels should be <5.0 mEq/L. Careful monitoring of potassium levels, renal function, and diuretic dosing should be performed at initiation and closely followed thereafter to minimize risk of hyperkalemia and renal insufficiency. | 32563 | patients with NYHA class II–IV | C0497661 | Aldosterone receptor antagonists (or mineralocorticoid receptor antagonists) | C3525772 |
Heart Failure 2017 ACC/AHA/HFSA | Throughout the hospitalization as appropriate, before hospital discharge, at the first postdischarge visit, and in subsequent follow-up visits, the following should be addressed (I-B): a. Initiation of GDMT if not previously established and not contraindicated b. Precipitant causes of Heart Failure, barriers to optimal care transitions, and limitations in postdischarge support c. Assessment of volume status and supine/upright hypotension with adjustment of Heart Failure therapy, as appropriate d. Titration and optimization of chronic oral Heart Failure therapy e. Assessment of renal function and electrolytes, where appropriate f. Assessment and management of comorbid conditions g. Reinforcement of Heart Failure education, self-care, emergency plans, and need for adherence h. Consideration for palliative care or hospice care in selected patients | 32629 | before hospital discharge, | C2362761 | Titration and optimization of chronic oral HF therapy | C2169312 |
Heart Failure 2017 ACC/AHA/HFSA | Throughout the hospitalization as appropriate, before hospital discharge, at the first postdischarge visit, and in subsequent follow-up visits, the following should be addressed (I-B): a. Initiation of GDMT if not previously established and not contraindicated b. Precipitant causes of Heart Failure, barriers to optimal care transitions, and limitations in postdischarge support c. Assessment of volume status and supine/upright hypotension with adjustment of Heart Failure therapy, as appropriate d. Titration and optimization of chronic oral Heart Failure therapy e. Assessment of renal function and electrolytes, where appropriate f. Assessment and management of comorbid conditions g. Reinforcement of Heart Failure education, self-care, emergency plans, and need for adherence h. Consideration for palliative care or hospice care in selected patients | 32629 | before hospital discharge, | C4291934 | Titration and optimization of chronic oral HF therapy | C2169312 |
Heart Failure 2017 ACC/AHA/HFSA | Throughout the hospitalization as appropriate, before hospital discharge, at the first postdischarge visit, and in subsequent follow-up visits, the following should be addressed (I-B): a. Initiation of GDMT if not previously established and not contraindicated b. Precipitant causes of Heart Failure, barriers to optimal care transitions, and limitations in postdischarge support c. Assessment of volume status and supine/upright hypotension with adjustment of Heart Failure therapy, as appropriate d. Titration and optimization of chronic oral Heart Failure therapy e. Assessment of renal function and electrolytes, where appropriate f. Assessment and management of comorbid conditions g. Reinforcement of Heart Failure education, self-care, emergency plans, and need for adherence h. Consideration for palliative care or hospice care in selected patients | 32629 | before hospital discharge, | C4291932 | Titration and optimization of chronic oral HF therapy | C2169312 |
Heart Failure 2017 ACC/AHA/HFSA | Throughout the hospitalization as appropriate, before hospital discharge, at the first postdischarge visit, and in subsequent follow-up visits, the following should be addressed (I-B): a. Initiation of GDMT if not previously established and not contraindicated b. Precipitant causes of Heart Failure, barriers to optimal care transitions, and limitations in postdischarge support c. Assessment of volume status and supine/upright hypotension with adjustment of Heart Failure therapy, as appropriate d. Titration and optimization of chronic oral Heart Failure therapy e. Assessment of renal function and electrolytes, where appropriate f. Assessment and management of comorbid conditions g. Reinforcement of Heart Failure education, self-care, emergency plans, and need for adherence h. Consideration for palliative care or hospice care in selected patients | 32629 | before hospital discharge, | C2362761 | Consideration for palliative care or hospice care in selected patients | C4291840 |
Heart Failure 2017 ACC/AHA/HFSA | Throughout the hospitalization as appropriate, before hospital discharge, at the first postdischarge visit, and in subsequent follow-up visits, the following should be addressed (I-B): a. Initiation of GDMT if not previously established and not contraindicated b. Precipitant causes of Heart Failure, barriers to optimal care transitions, and limitations in postdischarge support c. Assessment of volume status and supine/upright hypotension with adjustment of Heart Failure therapy, as appropriate d. Titration and optimization of chronic oral Heart Failure therapy e. Assessment of renal function and electrolytes, where appropriate f. Assessment and management of comorbid conditions g. Reinforcement of Heart Failure education, self-care, emergency plans, and need for adherence h. Consideration for palliative care or hospice care in selected patients | 32629 | before hospital discharge, | C4291934 | Consideration for palliative care or hospice care in selected patients | C4291840 |
Heart Failure 2017 ACC/AHA/HFSA | Throughout the hospitalization as appropriate, before hospital discharge, at the first postdischarge visit, and in subsequent follow-up visits, the following should be addressed (I-B): a. Initiation of GDMT if not previously established and not contraindicated b. Precipitant causes of Heart Failure, barriers to optimal care transitions, and limitations in postdischarge support c. Assessment of volume status and supine/upright hypotension with adjustment of Heart Failure therapy, as appropriate d. Titration and optimization of chronic oral Heart Failure therapy e. Assessment of renal function and electrolytes, where appropriate f. Assessment and management of comorbid conditions g. Reinforcement of Heart Failure education, self-care, emergency plans, and need for adherence h. Consideration for palliative care or hospice care in selected patients | 32629 | before hospital discharge, | C4291932 | Consideration for palliative care or hospice care in selected patients | C4291840 |
Heart Failure 2017 ACC/AHA/HFSA | Throughout the hospitalization as appropriate, before hospital discharge, at the first postdischarge visit, and in subsequent follow-up visits, the following should be addressed (I-B): a. Initiation of GDMT if not previously established and not contraindicated b. Precipitant causes of Heart Failure, barriers to optimal care transitions, and limitations in postdischarge support c. Assessment of volume status and supine/upright hypotension with adjustment of Heart Failure therapy, as appropriate d. Titration and optimization of chronic oral Heart Failure therapy e. Assessment of renal function and electrolytes, where appropriate f. Assessment and management of comorbid conditions g. Reinforcement of Heart Failure education, self-care, emergency plans, and need for adherence h. Consideration for palliative care or hospice care in selected patients | 32629 | before hospital discharge, | C2362761 | Consideration for palliative care or hospice care in selected patients | C3523469 |
Heart Failure 2017 ACC/AHA/HFSA | Throughout the hospitalization as appropriate, before hospital discharge, at the first postdischarge visit, and in subsequent follow-up visits, the following should be addressed (I-B): a. Initiation of GDMT if not previously established and not contraindicated b. Precipitant causes of Heart Failure, barriers to optimal care transitions, and limitations in postdischarge support c. Assessment of volume status and supine/upright hypotension with adjustment of Heart Failure therapy, as appropriate d. Titration and optimization of chronic oral Heart Failure therapy e. Assessment of renal function and electrolytes, where appropriate f. Assessment and management of comorbid conditions g. Reinforcement of Heart Failure education, self-care, emergency plans, and need for adherence h. Consideration for palliative care or hospice care in selected patients | 32629 | before hospital discharge, | C4291934 | Consideration for palliative care or hospice care in selected patients | C3523469 |
Heart Failure 2017 ACC/AHA/HFSA | Throughout the hospitalization as appropriate, before hospital discharge, at the first postdischarge visit, and in subsequent follow-up visits, the following should be addressed (I-B): a. Initiation of GDMT if not previously established and not contraindicated b. Precipitant causes of Heart Failure, barriers to optimal care transitions, and limitations in postdischarge support c. Assessment of volume status and supine/upright hypotension with adjustment of Heart Failure therapy, as appropriate d. Titration and optimization of chronic oral Heart Failure therapy e. Assessment of renal function and electrolytes, where appropriate f. Assessment and management of comorbid conditions g. Reinforcement of Heart Failure education, self-care, emergency plans, and need for adherence h. Consideration for palliative care or hospice care in selected patients | 32629 | before hospital discharge, | C4291932 | Consideration for palliative care or hospice care in selected patients | C3523469 |
Heart Failure 2017 ACC/AHA/HFSA | Throughout the hospitalization as appropriate, before hospital discharge, at the first postdischarge visit, and in subsequent follow-up visits, the following should be addressed (I-B): a. Initiation of GDMT if not previously established and not contraindicated b. Precipitant causes of Heart Failure, barriers to optimal care transitions, and limitations in postdischarge support c. Assessment of volume status and supine/upright hypotension with adjustment of Heart Failure therapy, as appropriate d. Titration and optimization of chronic oral Heart Failure therapy e. Assessment of renal function and electrolytes, where appropriate f. Assessment and management of comorbid conditions g. Reinforcement of Heart Failure education, self-care, emergency plans, and need for adherence h. Consideration for palliative care or hospice care in selected patients | 32629 | before hospital discharge, | C2362761 | Consideration for palliative care or hospice care in selected patients | C0033052 |
Heart Failure 2017 ACC/AHA/HFSA | Throughout the hospitalization as appropriate, before hospital discharge, at the first postdischarge visit, and in subsequent follow-up visits, the following should be addressed (I-B): a. Initiation of GDMT if not previously established and not contraindicated b. Precipitant causes of Heart Failure, barriers to optimal care transitions, and limitations in postdischarge support c. Assessment of volume status and supine/upright hypotension with adjustment of Heart Failure therapy, as appropriate d. Titration and optimization of chronic oral Heart Failure therapy e. Assessment of renal function and electrolytes, where appropriate f. Assessment and management of comorbid conditions g. Reinforcement of Heart Failure education, self-care, emergency plans, and need for adherence h. Consideration for palliative care or hospice care in selected patients | 32629 | before hospital discharge, | C4291934 | Consideration for palliative care or hospice care in selected patients | C0033052 |
Heart Failure 2017 ACC/AHA/HFSA | Throughout the hospitalization as appropriate, before hospital discharge, at the first postdischarge visit, and in subsequent follow-up visits, the following should be addressed (I-B): a. Initiation of GDMT if not previously established and not contraindicated b. Precipitant causes of Heart Failure, barriers to optimal care transitions, and limitations in postdischarge support c. Assessment of volume status and supine/upright hypotension with adjustment of Heart Failure therapy, as appropriate d. Titration and optimization of chronic oral Heart Failure therapy e. Assessment of renal function and electrolytes, where appropriate f. Assessment and management of comorbid conditions g. Reinforcement of Heart Failure education, self-care, emergency plans, and need for adherence h. Consideration for palliative care or hospice care in selected patients | 32629 | before hospital discharge, | C4291932 | Consideration for palliative care or hospice care in selected patients | C0033052 |
Heart Failure 2017 ACC/AHA/HFSA | Throughout the hospitalization as appropriate, before hospital discharge, at the first postdischarge visit, and in subsequent follow-up visits, the following should be addressed (I-B): a. Initiation of GDMT if not previously established and not contraindicated b. Precipitant causes of Heart Failure, barriers to optimal care transitions, and limitations in postdischarge support c. Assessment of volume status and supine/upright hypotension with adjustment of Heart Failure therapy, as appropriate d. Titration and optimization of chronic oral Heart Failure therapy e. Assessment of renal function and electrolytes, where appropriate f. Assessment and management of comorbid conditions g. Reinforcement of Heart Failure education, self-care, emergency plans, and need for adherence h. Consideration for palliative care or hospice care in selected patients | 32629 | before hospital discharge, | C2362761 | Consideration for palliative care or hospice care in selected patients | C0032782 |
Heart Failure 2017 ACC/AHA/HFSA | Throughout the hospitalization as appropriate, before hospital discharge, at the first postdischarge visit, and in subsequent follow-up visits, the following should be addressed (I-B): a. Initiation of GDMT if not previously established and not contraindicated b. Precipitant causes of Heart Failure, barriers to optimal care transitions, and limitations in postdischarge support c. Assessment of volume status and supine/upright hypotension with adjustment of Heart Failure therapy, as appropriate d. Titration and optimization of chronic oral Heart Failure therapy e. Assessment of renal function and electrolytes, where appropriate f. Assessment and management of comorbid conditions g. Reinforcement of Heart Failure education, self-care, emergency plans, and need for adherence h. Consideration for palliative care or hospice care in selected patients | 32629 | before hospital discharge, | C4291934 | Consideration for palliative care or hospice care in selected patients | C0032782 |
Heart Failure 2017 ACC/AHA/HFSA | Throughout the hospitalization as appropriate, before hospital discharge, at the first postdischarge visit, and in subsequent follow-up visits, the following should be addressed (I-B): a. Initiation of GDMT if not previously established and not contraindicated b. Precipitant causes of Heart Failure, barriers to optimal care transitions, and limitations in postdischarge support c. Assessment of volume status and supine/upright hypotension with adjustment of Heart Failure therapy, as appropriate d. Titration and optimization of chronic oral Heart Failure therapy e. Assessment of renal function and electrolytes, where appropriate f. Assessment and management of comorbid conditions g. Reinforcement of Heart Failure education, self-care, emergency plans, and need for adherence h. Consideration for palliative care or hospice care in selected patients | 32629 | before hospital discharge, | C4291932 | Consideration for palliative care or hospice care in selected patients | C0032782 |
Heart Failure 2017 ACC/AHA/HFSA | Throughout the hospitalization as appropriate, before hospital discharge, at the first postdischarge visit, and in subsequent follow-up visits, the following should be addressed (I-B): a. Initiation of GDMT if not previously established and not contraindicated b. Precipitant causes of Heart Failure, barriers to optimal care transitions, and limitations in postdischarge support c. Assessment of volume status and supine/upright hypotension with adjustment of Heart Failure therapy, as appropriate d. Titration and optimization of chronic oral Heart Failure therapy e. Assessment of renal function and electrolytes, where appropriate f. Assessment and management of comorbid conditions g. Reinforcement of Heart Failure education, self-care, emergency plans, and need for adherence h. Consideration for palliative care or hospice care in selected patients | 32629 | before hospital discharge, | C2362761 | Consideration for palliative care or hospice care in selected patients | C0195605 |
Heart Failure 2017 ACC/AHA/HFSA | Throughout the hospitalization as appropriate, before hospital discharge, at the first postdischarge visit, and in subsequent follow-up visits, the following should be addressed (I-B): a. Initiation of GDMT if not previously established and not contraindicated b. Precipitant causes of Heart Failure, barriers to optimal care transitions, and limitations in postdischarge support c. Assessment of volume status and supine/upright hypotension with adjustment of Heart Failure therapy, as appropriate d. Titration and optimization of chronic oral Heart Failure therapy e. Assessment of renal function and electrolytes, where appropriate f. Assessment and management of comorbid conditions g. Reinforcement of Heart Failure education, self-care, emergency plans, and need for adherence h. Consideration for palliative care or hospice care in selected patients | 32629 | before hospital discharge, | C4291934 | Consideration for palliative care or hospice care in selected patients | C0195605 |
Heart Failure 2017 ACC/AHA/HFSA | Throughout the hospitalization as appropriate, before hospital discharge, at the first postdischarge visit, and in subsequent follow-up visits, the following should be addressed (I-B): a. Initiation of GDMT if not previously established and not contraindicated b. Precipitant causes of Heart Failure, barriers to optimal care transitions, and limitations in postdischarge support c. Assessment of volume status and supine/upright hypotension with adjustment of Heart Failure therapy, as appropriate d. Titration and optimization of chronic oral Heart Failure therapy e. Assessment of renal function and electrolytes, where appropriate f. Assessment and management of comorbid conditions g. Reinforcement of Heart Failure education, self-care, emergency plans, and need for adherence h. Consideration for palliative care or hospice care in selected patients | 32629 | before hospital discharge, | C4291932 | Consideration for palliative care or hospice care in selected patients | C0195605 |
Heart Failure 2017 ACC/AHA/HFSA | In patients with cardiovascular disease and obstructive sleep apnea, CPAP may be reasonable to improve sleep quality and daytime sleepiness | 32639 | In patients with cardiovascular disease | C3526717 | continuous positive airway pressure may be reasonable | C0199451 |
Heart Failure 2017 ACC/AHA/HFSA | In patients with cardiovascular disease and obstructive sleep apnea, CPAP may be reasonable to improve sleep quality and daytime sleepiness | 32639 | In patients with cardiovascular disease | C0973439 | continuous positive airway pressure may be reasonable | C0199451 |
Heart Failure 2017 ACC/AHA/HFSA | In patients with cardiovascular disease and obstructive sleep apnea, CPAP may be reasonable to improve sleep quality and daytime sleepiness | 32639 | In patients with cardiovascular disease | C0973444 | continuous positive airway pressure may be reasonable | C0199451 |
Heart Failure 2017 ACC/AHA/HFSA | In patients with cardiovascular disease and obstructive sleep apnea, CPAP may be reasonable to improve sleep quality and daytime sleepiness | 32639 | obstructive sleep apnea | C4291861 | continuous positive airway pressure may be reasonable | C0199451 |
Heart Failure 2017 ACC/AHA/HFSA | In patients with cardiovascular disease and obstructive sleep apnea, CPAP may be reasonable to improve sleep quality and daytime sleepiness | 32639 | obstructive sleep apnea | C4291860 | continuous positive airway pressure may be reasonable | C0199451 |
Heart Failure 2017 ACC/AHA/HFSA | In patients with cardiovascular disease and obstructive sleep apnea, CPAP may be reasonable to improve sleep quality and daytime sleepiness | 32639 | obstructive sleep apnea | C3704075 | continuous positive airway pressure may be reasonable | C0199451 |
Heart Failure 2017 ACC/AHA/HFSA | In patients with cardiovascular disease and obstructive sleep apnea, CPAP may be reasonable to improve sleep quality and daytime sleepiness | 32639 | obstructive sleep apnea | C3517193 | continuous positive airway pressure may be reasonable | C0199451 |
Heart Failure 2017 ACC/AHA/HFSA | In patients with cardiovascular disease and obstructive sleep apnea, CPAP may be reasonable to improve sleep quality and daytime sleepiness | 32639 | obstructive sleep apnea | C0200101 | continuous positive airway pressure may be reasonable | C0199451 |
Heart Failure 2017 ACC/AHA/HFSA | In patients with cardiovascular disease and obstructive sleep apnea, CPAP may be reasonable to improve sleep quality and daytime sleepiness | 32639 | obstructive sleep apnea | C4291859 | continuous positive airway pressure may be reasonable | C0199451 |
Heart Failure 2017 ACC/AHA/HFSA | In patients with cardiovascular disease and obstructive sleep apnea, CPAP may be reasonable to improve sleep quality and daytime sleepiness | 32639 | obstructive sleep apnea | C4067660 | continuous positive airway pressure may be reasonable | C0199451 |
Heart Failure 2017 ACC/AHA/HFSA | In patients with cardiovascular disease and obstructive sleep apnea, CPAP may be reasonable to improve sleep quality and daytime sleepiness | 32639 | In patients with cardiovascular disease | C3526717 | continuous positive airway pressure may be reasonable | C0374380 |
Heart Failure 2017 ACC/AHA/HFSA | In patients with cardiovascular disease and obstructive sleep apnea, CPAP may be reasonable to improve sleep quality and daytime sleepiness | 32639 | In patients with cardiovascular disease | C0973439 | continuous positive airway pressure may be reasonable | C0374380 |
Heart Failure 2017 ACC/AHA/HFSA | In patients with cardiovascular disease and obstructive sleep apnea, CPAP may be reasonable to improve sleep quality and daytime sleepiness | 32639 | In patients with cardiovascular disease | C0973444 | continuous positive airway pressure may be reasonable | C0374380 |
Heart Failure 2017 ACC/AHA/HFSA | In patients with cardiovascular disease and obstructive sleep apnea, CPAP may be reasonable to improve sleep quality and daytime sleepiness | 32639 | obstructive sleep apnea | C4291861 | continuous positive airway pressure may be reasonable | C0374380 |
Heart Failure 2017 ACC/AHA/HFSA | In patients with cardiovascular disease and obstructive sleep apnea, CPAP may be reasonable to improve sleep quality and daytime sleepiness | 32639 | obstructive sleep apnea | C4291860 | continuous positive airway pressure may be reasonable | C0374380 |
Heart Failure 2017 ACC/AHA/HFSA | In patients with cardiovascular disease and obstructive sleep apnea, CPAP may be reasonable to improve sleep quality and daytime sleepiness | 32639 | obstructive sleep apnea | C3704075 | continuous positive airway pressure may be reasonable | C0374380 |
Heart Failure 2017 ACC/AHA/HFSA | In patients with cardiovascular disease and obstructive sleep apnea, CPAP may be reasonable to improve sleep quality and daytime sleepiness | 32639 | obstructive sleep apnea | C3517193 | continuous positive airway pressure may be reasonable | C0374380 |
Heart Failure 2017 ACC/AHA/HFSA | In patients with cardiovascular disease and obstructive sleep apnea, CPAP may be reasonable to improve sleep quality and daytime sleepiness | 32639 | obstructive sleep apnea | C0200101 | continuous positive airway pressure may be reasonable | C0374380 |
Heart Failure 2017 ACC/AHA/HFSA | In patients with cardiovascular disease and obstructive sleep apnea, CPAP may be reasonable to improve sleep quality and daytime sleepiness | 32639 | obstructive sleep apnea | C4291859 | continuous positive airway pressure may be reasonable | C0374380 |
Heart Failure 2017 ACC/AHA/HFSA | In patients with cardiovascular disease and obstructive sleep apnea, CPAP may be reasonable to improve sleep quality and daytime sleepiness | 32639 | obstructive sleep apnea | C4067660 | continuous positive airway pressure may be reasonable | C0374380 |
Heart Failure 2017 ACC/AHA/HFSA | Coronary artery revascularization via coronary artery bypass graft (CABG) or percutaneous intervention is indicated for patients (Heart FailurepEF and Heart FailurerEF) on GDMT with angina and suitable coronary anatomy, especially for a left main stenosis (>50%) or left main–equivalent disease. (I-C) | 32641 | with angina | C3248525 | Coronary artery revascularization via coronary artery bypass graft | C0371556 |
Heart Failure 2017 ACC/AHA/HFSA | Coronary artery revascularization via coronary artery bypass graft (CABG) or percutaneous intervention is indicated for patients (Heart FailurepEF and Heart FailurerEF) on GDMT with angina and suitable coronary anatomy, especially for a left main stenosis (>50%) or left main–equivalent disease. (I-C) | 32641 | with angina | C3248257 | Coronary artery revascularization via coronary artery bypass graft | C0371556 |
Heart Failure 2017 ACC/AHA/HFSA | Coronary artery revascularization via coronary artery bypass graft (CABG) or percutaneous intervention is indicated for patients (Heart FailurepEF and Heart FailurerEF) on GDMT with angina and suitable coronary anatomy, especially for a left main stenosis (>50%) or left main–equivalent disease. (I-C) | 32641 | with angina | C3248525 | Coronary artery revascularization via coronary artery bypass graft | C1261082 |
Heart Failure 2017 ACC/AHA/HFSA | Coronary artery revascularization via coronary artery bypass graft (CABG) or percutaneous intervention is indicated for patients (Heart FailurepEF and Heart FailurerEF) on GDMT with angina and suitable coronary anatomy, especially for a left main stenosis (>50%) or left main–equivalent disease. (I-C) | 32641 | with angina | C3248257 | Coronary artery revascularization via coronary artery bypass graft | C1261082 |
Heart Failure 2017 ACC/AHA/HFSA | Coronary artery revascularization via coronary artery bypass graft (CABG) or percutaneous intervention is indicated for patients (Heart FailurepEF and Heart FailurerEF) on GDMT with angina and suitable coronary anatomy, especially for a left main stenosis (>50%) or left main–equivalent disease. (I-C) | 32641 | with angina | C3248525 | Coronary artery revascularization via coronary artery bypass graft | C0371555 |
Heart Failure 2017 ACC/AHA/HFSA | Coronary artery revascularization via coronary artery bypass graft (CABG) or percutaneous intervention is indicated for patients (Heart FailurepEF and Heart FailurerEF) on GDMT with angina and suitable coronary anatomy, especially for a left main stenosis (>50%) or left main–equivalent disease. (I-C) | 32641 | with angina | C3248257 | Coronary artery revascularization via coronary artery bypass graft | C0371555 |
Heart Failure 2017 ACC/AHA/HFSA | Coronary artery revascularization via coronary artery bypass graft (CABG) or percutaneous intervention is indicated for patients (Heart FailurepEF and Heart FailurerEF) on GDMT with angina and suitable coronary anatomy, especially for a left main stenosis (>50%) or left main–equivalent disease. (I-C) | 32641 | with angina | C3248525 | Coronary artery revascularization via coronary artery bypass graft | C0371554 |
Heart Failure 2017 ACC/AHA/HFSA | Coronary artery revascularization via coronary artery bypass graft (CABG) or percutaneous intervention is indicated for patients (Heart FailurepEF and Heart FailurerEF) on GDMT with angina and suitable coronary anatomy, especially for a left main stenosis (>50%) or left main–equivalent disease. (I-C) | 32641 | with angina | C3248257 | Coronary artery revascularization via coronary artery bypass graft | C0371554 |
Heart Failure 2017 ACC/AHA/HFSA | Coronary artery revascularization via coronary artery bypass graft (CABG) or percutaneous intervention is indicated for patients (Heart FailurepEF and Heart FailurerEF) on GDMT with angina and suitable coronary anatomy, especially for a left main stenosis (>50%) or left main–equivalent disease. (I-C) | 32641 | with angina | C3248525 | Coronary artery revascularization via coronary artery bypass graft | C0371553 |
Heart Failure 2017 ACC/AHA/HFSA | Coronary artery revascularization via coronary artery bypass graft (CABG) or percutaneous intervention is indicated for patients (Heart FailurepEF and Heart FailurerEF) on GDMT with angina and suitable coronary anatomy, especially for a left main stenosis (>50%) or left main–equivalent disease. (I-C) | 32641 | with angina | C3248257 | Coronary artery revascularization via coronary artery bypass graft | C0371553 |
Heart Failure 2017 ACC/AHA/HFSA | Coronary artery revascularization via coronary artery bypass graft (CABG) or percutaneous intervention is indicated for patients (Heart FailurepEF and Heart FailurerEF) on GDMT with angina and suitable coronary anatomy, especially for a left main stenosis (>50%) or left main–equivalent disease. (I-C) | 32641 | with angina | C3248525 | Coronary artery revascularization via coronary artery bypass graft | C0371552 |
Heart Failure 2017 ACC/AHA/HFSA | Coronary artery revascularization via coronary artery bypass graft (CABG) or percutaneous intervention is indicated for patients (Heart FailurepEF and Heart FailurerEF) on GDMT with angina and suitable coronary anatomy, especially for a left main stenosis (>50%) or left main–equivalent disease. (I-C) | 32641 | with angina | C3248257 | Coronary artery revascularization via coronary artery bypass graft | C0371552 |
Heart Failure 2017 ACC/AHA/HFSA | Coronary artery revascularization via coronary artery bypass graft (CABG) or percutaneous intervention is indicated for patients (Heart FailurepEF and Heart FailurerEF) on GDMT with angina and suitable coronary anatomy, especially for a left main stenosis (>50%) or left main–equivalent disease. (I-C) | 32641 | with angina | C3248525 | Coronary artery revascularization via coronary artery bypass graft | C0371551 |
Heart Failure 2017 ACC/AHA/HFSA | Coronary artery revascularization via coronary artery bypass graft (CABG) or percutaneous intervention is indicated for patients (Heart FailurepEF and Heart FailurerEF) on GDMT with angina and suitable coronary anatomy, especially for a left main stenosis (>50%) or left main–equivalent disease. (I-C) | 32641 | with angina | C3248257 | Coronary artery revascularization via coronary artery bypass graft | C0371551 |
Heart Failure 2017 ACC/AHA/HFSA | Coronary artery revascularization via coronary artery bypass graft (CABG) or percutaneous intervention is indicated for patients (Heart FailurepEF and Heart FailurerEF) on GDMT with angina and suitable coronary anatomy, especially for a left main stenosis (>50%) or left main–equivalent disease. (I-C) | 32641 | with angina | C3248525 | Coronary artery revascularization via coronary artery bypass graft | C3534821 |
Heart Failure 2017 ACC/AHA/HFSA | Coronary artery revascularization via coronary artery bypass graft (CABG) or percutaneous intervention is indicated for patients (Heart FailurepEF and Heart FailurerEF) on GDMT with angina and suitable coronary anatomy, especially for a left main stenosis (>50%) or left main–equivalent disease. (I-C) | 32641 | with angina | C3248257 | Coronary artery revascularization via coronary artery bypass graft | C3534821 |
Heart Failure 2017 ACC/AHA/HFSA | Coronary artery revascularization via coronary artery bypass graft (CABG) or percutaneous intervention is indicated for patients (Heart FailurepEF and Heart FailurerEF) on GDMT with angina and suitable coronary anatomy, especially for a left main stenosis (>50%) or left main–equivalent disease. (I-C) | 32641 | with angina | C3248525 | Coronary artery revascularization via coronary artery bypass graft | C0519385 |
Heart Failure 2017 ACC/AHA/HFSA | Coronary artery revascularization via coronary artery bypass graft (CABG) or percutaneous intervention is indicated for patients (Heart FailurepEF and Heart FailurerEF) on GDMT with angina and suitable coronary anatomy, especially for a left main stenosis (>50%) or left main–equivalent disease. (I-C) | 32641 | with angina | C3248257 | Coronary artery revascularization via coronary artery bypass graft | C0519385 |
Heart Failure 2017 ACC/AHA/HFSA | Coronary artery revascularization via coronary artery bypass graft (CABG) or percutaneous intervention is indicated for patients (Heart FailurepEF and Heart FailurerEF) on GDMT with angina and suitable coronary anatomy, especially for a left main stenosis (>50%) or left main–equivalent disease. (I-C) | 32641 | with angina | C3248525 | Coronary artery revascularization via coronary artery bypass graft | C0226032 |
Heart Failure 2017 ACC/AHA/HFSA | Coronary artery revascularization via coronary artery bypass graft (CABG) or percutaneous intervention is indicated for patients (Heart FailurepEF and Heart FailurerEF) on GDMT with angina and suitable coronary anatomy, especially for a left main stenosis (>50%) or left main–equivalent disease. (I-C) | 32641 | with angina | C3248257 | Coronary artery revascularization via coronary artery bypass graft | C0226032 |
Heart Failure 2017 ACC/AHA/HFSA | Coronary artery revascularization via coronary artery bypass graft (CABG) or percutaneous intervention is indicated for patients (Heart FailurepEF and Heart FailurerEF) on GDMT with angina and suitable coronary anatomy, especially for a left main stenosis (>50%) or left main–equivalent disease. (I-C) | 32641 | with angina | C3248525 | Coronary artery revascularization via coronary artery bypass graft | C0190195 |
Heart Failure 2017 ACC/AHA/HFSA | Coronary artery revascularization via coronary artery bypass graft (CABG) or percutaneous intervention is indicated for patients (Heart FailurepEF and Heart FailurerEF) on GDMT with angina and suitable coronary anatomy, especially for a left main stenosis (>50%) or left main–equivalent disease. (I-C) | 32641 | with angina | C3248257 | Coronary artery revascularization via coronary artery bypass graft | C0190195 |
Heart Failure 2017 ACC/AHA/HFSA | Coronary artery revascularization via coronary artery bypass graft (CABG) or percutaneous intervention is indicated for patients (Heart FailurepEF and Heart FailurerEF) on GDMT with angina and suitable coronary anatomy, especially for a left main stenosis (>50%) or left main–equivalent disease. (I-C) | 32641 | with angina | C3248525 | Coronary artery revascularization via coronary artery bypass graft | C3869357 |
Heart Failure 2017 ACC/AHA/HFSA | Coronary artery revascularization via coronary artery bypass graft (CABG) or percutaneous intervention is indicated for patients (Heart FailurepEF and Heart FailurerEF) on GDMT with angina and suitable coronary anatomy, especially for a left main stenosis (>50%) or left main–equivalent disease. (I-C) | 32641 | with angina | C3248257 | Coronary artery revascularization via coronary artery bypass graft | C3869357 |
Heart Failure 2017 ACC/AHA/HFSA | Coronary artery revascularization via coronary artery bypass graft (CABG) or percutaneous intervention is indicated for patients (Heart FailurepEF and Heart FailurerEF) on GDMT with angina and suitable coronary anatomy, especially for a left main stenosis (>50%) or left main–equivalent disease. (I-C) | 32641 | with angina | C3248525 | Coronary artery revascularization via coronary artery bypass graft | C0190256 |
Heart Failure 2017 ACC/AHA/HFSA | Coronary artery revascularization via coronary artery bypass graft (CABG) or percutaneous intervention is indicated for patients (Heart FailurepEF and Heart FailurerEF) on GDMT with angina and suitable coronary anatomy, especially for a left main stenosis (>50%) or left main–equivalent disease. (I-C) | 32641 | with angina | C3248257 | Coronary artery revascularization via coronary artery bypass graft | C0190256 |
Heart Failure 2017 ACC/AHA/HFSA | Coronary artery revascularization via coronary artery bypass graft (CABG) or percutaneous intervention is indicated for patients (Heart FailurepEF and Heart FailurerEF) on GDMT with angina and suitable coronary anatomy, especially for a left main stenosis (>50%) or left main–equivalent disease. (I-C) | 32641 | with angina | C3248525 | Coronary artery revascularization via coronary artery bypass graft | C0226037 |
Heart Failure 2017 ACC/AHA/HFSA | Coronary artery revascularization via coronary artery bypass graft (CABG) or percutaneous intervention is indicated for patients (Heart FailurepEF and Heart FailurerEF) on GDMT with angina and suitable coronary anatomy, especially for a left main stenosis (>50%) or left main–equivalent disease. (I-C) | 32641 | with angina | C3248257 | Coronary artery revascularization via coronary artery bypass graft | C0226037 |
Heart Failure 2017 ACC/AHA/HFSA | Coronary artery revascularization via coronary artery bypass graft (CABG) or percutaneous intervention is indicated for patients (Heart FailurepEF and Heart FailurerEF) on GDMT with angina and suitable coronary anatomy, especially for a left main stenosis (>50%) or left main–equivalent disease. (I-C) | 32641 | with angina | C3248525 | Coronary artery revascularization via coronary artery bypass graft | C3511594 |
Heart Failure 2017 ACC/AHA/HFSA | Coronary artery revascularization via coronary artery bypass graft (CABG) or percutaneous intervention is indicated for patients (Heart FailurepEF and Heart FailurerEF) on GDMT with angina and suitable coronary anatomy, especially for a left main stenosis (>50%) or left main–equivalent disease. (I-C) | 32641 | with angina | C3248257 | Coronary artery revascularization via coronary artery bypass graft | C3511594 |
Heart Failure 2017 ACC/AHA/HFSA | Coronary artery revascularization via coronary artery bypass graft (CABG) or percutaneous intervention is indicated for patients (Heart FailurepEF and Heart FailurerEF) on GDMT with angina and suitable coronary anatomy, especially for a left main stenosis (>50%) or left main–equivalent disease. (I-C) | 32641 | with angina | C3248525 | Coronary artery revascularization via coronary artery bypass graft | C0810126 |
Heart Failure 2017 ACC/AHA/HFSA | Coronary artery revascularization via coronary artery bypass graft (CABG) or percutaneous intervention is indicated for patients (Heart FailurepEF and Heart FailurerEF) on GDMT with angina and suitable coronary anatomy, especially for a left main stenosis (>50%) or left main–equivalent disease. (I-C) | 32641 | with angina | C3248257 | Coronary artery revascularization via coronary artery bypass graft | C0810126 |
Heart Failure 2017 ACC/AHA/HFSA | Coronary artery revascularization via coronary artery bypass graft (CABG) or percutaneous intervention is indicated for patients (Heart FailurepEF and Heart FailurerEF) on GDMT with angina and suitable coronary anatomy, especially for a left main stenosis (>50%) or left main–equivalent disease. (I-C) | 32641 | with angina | C3248525 | Coronary artery revascularization via coronary artery bypass graft | C1261316 |
Heart Failure 2017 ACC/AHA/HFSA | Coronary artery revascularization via coronary artery bypass graft (CABG) or percutaneous intervention is indicated for patients (Heart FailurepEF and Heart FailurerEF) on GDMT with angina and suitable coronary anatomy, especially for a left main stenosis (>50%) or left main–equivalent disease. (I-C) | 32641 | with angina | C3248257 | Coronary artery revascularization via coronary artery bypass graft | C1261316 |
Heart Failure 2017 ACC/AHA/HFSA | Coronary artery revascularization via coronary artery bypass graft (CABG) or percutaneous intervention is indicated for patients (Heart FailurepEF and Heart FailurerEF) on GDMT with angina and suitable coronary anatomy, especially for a left main stenosis (>50%) or left main–equivalent disease. (I-C) | 32641 | with angina | C3248525 | Coronary artery revascularization via coronary artery bypass graft | C3867326 |
Heart Failure 2017 ACC/AHA/HFSA | Coronary artery revascularization via coronary artery bypass graft (CABG) or percutaneous intervention is indicated for patients (Heart FailurepEF and Heart FailurerEF) on GDMT with angina and suitable coronary anatomy, especially for a left main stenosis (>50%) or left main–equivalent disease. (I-C) | 32641 | with angina | C3248257 | Coronary artery revascularization via coronary artery bypass graft | C3867326 |
Heart Failure 2017 ACC/AHA/HFSA | Coronary artery revascularization via coronary artery bypass graft (CABG) or percutaneous intervention is indicated for patients (Heart FailurepEF and Heart FailurerEF) on GDMT with angina and suitable coronary anatomy, especially for a left main stenosis (>50%) or left main–equivalent disease. (I-C) | 32641 | with angina | C3248525 | Coronary artery revascularization via coronary artery bypass graft | C3520611 |
Heart Failure 2017 ACC/AHA/HFSA | Coronary artery revascularization via coronary artery bypass graft (CABG) or percutaneous intervention is indicated for patients (Heart FailurepEF and Heart FailurerEF) on GDMT with angina and suitable coronary anatomy, especially for a left main stenosis (>50%) or left main–equivalent disease. (I-C) | 32641 | with angina | C3248257 | Coronary artery revascularization via coronary artery bypass graft | C3520611 |
Heart Failure 2017 ACC/AHA/HFSA | Coronary artery revascularization via coronary artery bypass graft (CABG) or percutaneous intervention is indicated for patients (Heart FailurepEF and Heart FailurerEF) on GDMT with angina and suitable coronary anatomy, especially for a left main stenosis (>50%) or left main–equivalent disease. (I-C) | 32641 | with angina | C3248525 | Coronary artery revascularization via coronary artery bypass graft | C3513523 |
Heart Failure 2017 ACC/AHA/HFSA | Coronary artery revascularization via coronary artery bypass graft (CABG) or percutaneous intervention is indicated for patients (Heart FailurepEF and Heart FailurerEF) on GDMT with angina and suitable coronary anatomy, especially for a left main stenosis (>50%) or left main–equivalent disease. (I-C) | 32641 | with angina | C3248257 | Coronary artery revascularization via coronary artery bypass graft | C3513523 |
Heart Failure 2017 ACC/AHA/HFSA | Coronary artery revascularization via coronary artery bypass graft (CABG) or percutaneous intervention is indicated for patients (Heart FailurepEF and Heart FailurerEF) on GDMT with angina and suitable coronary anatomy, especially for a left main stenosis (>50%) or left main–equivalent disease. (I-C) | 32641 | with angina | C3248525 | Coronary artery revascularization via coronary artery bypass graft | C3513521 |
Heart Failure 2017 ACC/AHA/HFSA | Coronary artery revascularization via coronary artery bypass graft (CABG) or percutaneous intervention is indicated for patients (Heart FailurepEF and Heart FailurerEF) on GDMT with angina and suitable coronary anatomy, especially for a left main stenosis (>50%) or left main–equivalent disease. (I-C) | 32641 | with angina | C3248257 | Coronary artery revascularization via coronary artery bypass graft | C3513521 |
Heart Failure 2017 ACC/AHA/HFSA | Coronary artery revascularization via coronary artery bypass graft (CABG) or percutaneous intervention is indicated for patients (Heart FailurepEF and Heart FailurerEF) on GDMT with angina and suitable coronary anatomy, especially for a left main stenosis (>50%) or left main–equivalent disease. (I-C) | 32641 | with angina | C3248525 | Coronary artery revascularization via coronary artery bypass graft | C3868273 |
Heart Failure 2017 ACC/AHA/HFSA | Coronary artery revascularization via coronary artery bypass graft (CABG) or percutaneous intervention is indicated for patients (Heart FailurepEF and Heart FailurerEF) on GDMT with angina and suitable coronary anatomy, especially for a left main stenosis (>50%) or left main–equivalent disease. (I-C) | 32641 | with angina | C3248257 | Coronary artery revascularization via coronary artery bypass graft | C3868273 |
Heart Failure 2017 ACC/AHA/HFSA | Coronary artery revascularization via coronary artery bypass graft (CABG) or percutaneous intervention is indicated for patients (Heart FailurepEF and Heart FailurerEF) on GDMT with angina and suitable coronary anatomy, especially for a left main stenosis (>50%) or left main–equivalent disease. (I-C) | 32641 | with angina | C3248525 | Coronary artery revascularization via coronary artery bypass graft | C0371548 |
Heart Failure 2017 ACC/AHA/HFSA | Coronary artery revascularization via coronary artery bypass graft (CABG) or percutaneous intervention is indicated for patients (Heart FailurepEF and Heart FailurerEF) on GDMT with angina and suitable coronary anatomy, especially for a left main stenosis (>50%) or left main–equivalent disease. (I-C) | 32641 | with angina | C3248257 | Coronary artery revascularization via coronary artery bypass graft | C0371548 |
Heart Failure 2017 ACC/AHA/HFSA | Coronary artery revascularization via coronary artery bypass graft (CABG) or percutaneous intervention is indicated for patients (Heart FailurepEF and Heart FailurerEF) on GDMT with angina and suitable coronary anatomy, especially for a left main stenosis (>50%) or left main–equivalent disease. (I-C) | 32641 | with angina | C3248525 | Coronary artery revascularization via coronary artery bypass graft | C0189584 |
Heart Failure 2017 ACC/AHA/HFSA | Coronary artery revascularization via coronary artery bypass graft (CABG) or percutaneous intervention is indicated for patients (Heart FailurepEF and Heart FailurerEF) on GDMT with angina and suitable coronary anatomy, especially for a left main stenosis (>50%) or left main–equivalent disease. (I-C) | 32641 | with angina | C3248257 | Coronary artery revascularization via coronary artery bypass graft | C0189584 |
Heart Failure 2017 ACC/AHA/HFSA | Coronary artery revascularization via coronary artery bypass graft (CABG) or percutaneous intervention is indicated for patients (Heart FailurepEF and Heart FailurerEF) on GDMT with angina and suitable coronary anatomy, especially for a left main stenosis (>50%) or left main–equivalent disease. (I-C) | 32641 | with angina | C3248525 | Coronary artery revascularization via coronary artery bypass graft | C3526698 |
Heart Failure 2017 ACC/AHA/HFSA | Coronary artery revascularization via coronary artery bypass graft (CABG) or percutaneous intervention is indicated for patients (Heart FailurepEF and Heart FailurerEF) on GDMT with angina and suitable coronary anatomy, especially for a left main stenosis (>50%) or left main–equivalent disease. (I-C) | 32641 | with angina | C3248257 | Coronary artery revascularization via coronary artery bypass graft | C3526698 |
Heart Failure 2017 ACC/AHA/HFSA | Coronary artery revascularization via coronary artery bypass graft (CABG) or percutaneous intervention is indicated for patients (Heart FailurepEF and Heart FailurerEF) on GDMT with angina and suitable coronary anatomy, especially for a left main stenosis (>50%) or left main–equivalent disease. (I-C) | 32641 | with angina | C3248525 | Coronary artery revascularization via coronary artery bypass graft | C3526696 |
Heart Failure 2017 ACC/AHA/HFSA | Coronary artery revascularization via coronary artery bypass graft (CABG) or percutaneous intervention is indicated for patients (Heart FailurepEF and Heart FailurerEF) on GDMT with angina and suitable coronary anatomy, especially for a left main stenosis (>50%) or left main–equivalent disease. (I-C) | 32641 | with angina | C3248257 | Coronary artery revascularization via coronary artery bypass graft | C3526696 |
Heart Failure 2017 ACC/AHA/HFSA | Coronary artery revascularization via coronary artery bypass graft (CABG) or percutaneous intervention is indicated for patients (Heart FailurepEF and Heart FailurerEF) on GDMT with angina and suitable coronary anatomy, especially for a left main stenosis (>50%) or left main–equivalent disease. (I-C) | 32641 | with angina | C3248525 | Coronary artery revascularization via coronary artery bypass graft | C0371843 |
Heart Failure 2017 ACC/AHA/HFSA | Coronary artery revascularization via coronary artery bypass graft (CABG) or percutaneous intervention is indicated for patients (Heart FailurepEF and Heart FailurerEF) on GDMT with angina and suitable coronary anatomy, especially for a left main stenosis (>50%) or left main–equivalent disease. (I-C) | 32641 | with angina | C3248257 | Coronary artery revascularization via coronary artery bypass graft | C0371843 |
Heart Failure 2017 ACC/AHA/HFSA | Coronary artery revascularization via coronary artery bypass graft (CABG) or percutaneous intervention is indicated for patients (Heart FailurepEF and Heart FailurerEF) on GDMT with angina and suitable coronary anatomy, especially for a left main stenosis (>50%) or left main–equivalent disease. (I-C) | 32641 | with angina | C3248525 | Coronary artery revascularization via coronary artery bypass graft | C3526701 |
Heart Failure 2017 ACC/AHA/HFSA | Coronary artery revascularization via coronary artery bypass graft (CABG) or percutaneous intervention is indicated for patients (Heart FailurepEF and Heart FailurerEF) on GDMT with angina and suitable coronary anatomy, especially for a left main stenosis (>50%) or left main–equivalent disease. (I-C) | 32641 | with angina | C3248257 | Coronary artery revascularization via coronary artery bypass graft | C3526701 |
Heart Failure 2017 ACC/AHA/HFSA | Coronary artery revascularization via coronary artery bypass graft (CABG) or percutaneous intervention is indicated for patients (Heart FailurepEF and Heart FailurerEF) on GDMT with angina and suitable coronary anatomy, especially for a left main stenosis (>50%) or left main–equivalent disease. (I-C) | 32641 | with angina | C3248525 | Coronary artery revascularization via coronary artery bypass graft | C3513588 |
Heart Failure 2017 ACC/AHA/HFSA | Coronary artery revascularization via coronary artery bypass graft (CABG) or percutaneous intervention is indicated for patients (Heart FailurepEF and Heart FailurerEF) on GDMT with angina and suitable coronary anatomy, especially for a left main stenosis (>50%) or left main–equivalent disease. (I-C) | 32641 | with angina | C3248257 | Coronary artery revascularization via coronary artery bypass graft | C3513588 |
Heart Failure 2017 ACC/AHA/HFSA | Coronary artery revascularization via coronary artery bypass graft (CABG) or percutaneous intervention is indicated for patients (Heart FailurepEF and Heart FailurerEF) on GDMT with angina and suitable coronary anatomy, especially for a left main stenosis (>50%) or left main–equivalent disease. (I-C) | 32641 | with angina | C3248525 | Coronary artery revascularization via coronary artery bypass graft | C0185098 |
Heart Failure 2017 ACC/AHA/HFSA | Coronary artery revascularization via coronary artery bypass graft (CABG) or percutaneous intervention is indicated for patients (Heart FailurepEF and Heart FailurerEF) on GDMT with angina and suitable coronary anatomy, especially for a left main stenosis (>50%) or left main–equivalent disease. (I-C) | 32641 | with angina | C3248257 | Coronary artery revascularization via coronary artery bypass graft | C0185098 |
Heart Failure 2017 ACC/AHA/HFSA | Coronary artery revascularization via coronary artery bypass graft (CABG) or percutaneous intervention is indicated for patients (Heart FailurepEF and Heart FailurerEF) on GDMT with angina and suitable coronary anatomy, especially for a left main stenosis (>50%) or left main–equivalent disease. (I-C) | 32641 | with angina | C3248525 | Coronary artery revascularization via coronary artery bypass graft | C0371564 |
Heart Failure 2017 ACC/AHA/HFSA | Coronary artery revascularization via coronary artery bypass graft (CABG) or percutaneous intervention is indicated for patients (Heart FailurepEF and Heart FailurerEF) on GDMT with angina and suitable coronary anatomy, especially for a left main stenosis (>50%) or left main–equivalent disease. (I-C) | 32641 | with angina | C3248257 | Coronary artery revascularization via coronary artery bypass graft | C0371564 |
Heart Failure 2017 ACC/AHA/HFSA | Coronary artery revascularization via coronary artery bypass graft (CABG) or percutaneous intervention is indicated for patients (Heart FailurepEF and Heart FailurerEF) on GDMT with angina and suitable coronary anatomy, especially for a left main stenosis (>50%) or left main–equivalent disease. (I-C) | 32641 | with angina | C3248525 | or percutaneous intervention | C0190176 |
Heart Failure 2017 ACC/AHA/HFSA | Coronary artery revascularization via coronary artery bypass graft (CABG) or percutaneous intervention is indicated for patients (Heart FailurepEF and Heart FailurerEF) on GDMT with angina and suitable coronary anatomy, especially for a left main stenosis (>50%) or left main–equivalent disease. (I-C) | 32641 | with angina | C3248257 | or percutaneous intervention | C0190176 |
Heart Failure 2017 ACC/AHA/HFSA | Coronary artery revascularization via coronary artery bypass graft (CABG) or percutaneous intervention is indicated for patients (Heart FailurepEF and Heart FailurerEF) on GDMT with angina and suitable coronary anatomy, especially for a left main stenosis (>50%) or left main–equivalent disease. (I-C) | 32641 | with angina | C3248525 | or percutaneous intervention | C0162428 |
Heart Failure 2017 ACC/AHA/HFSA | Coronary artery revascularization via coronary artery bypass graft (CABG) or percutaneous intervention is indicated for patients (Heart FailurepEF and Heart FailurerEF) on GDMT with angina and suitable coronary anatomy, especially for a left main stenosis (>50%) or left main–equivalent disease. (I-C) | 32641 | with angina | C3248257 | or percutaneous intervention | C0162428 |
Heart Failure 2017 ACC/AHA/HFSA | Radionuclide ventriculography or magnetic resonance imaging can be useful to assess LVEF and volume when echocardiography is inadequate. | 32490 | echocardiography is inadequate | C0013516 | magnetic resonance imaging | C0024485 |